Michael Zinda
CIK 1815366 · EVP, CHIEF SCIENTIFIC OFFICER · last filed 2025-03-14
Michael Zinda is an EVP, CHIEF SCIENTIFIC OFFICER who has filed 22 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing shows the insider sold $6.4K of RPTX on Mar 14, 2025. Across all open-market trades the lifetime net is −$6.7M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RPTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
7210 FREDERICK-BANTING, SUITE 100
ST-LAURENT, A8 H4S 2A1
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Repare Therapeutics Inc. (RPTX) Delisted | EVP, CHIEF SCIENTIFIC OFFICER | 80,297 | $2.65 | $212.8K | -$6.67M | 20 | 2025-03-14 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-14 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −5,611 | -$6.4K | EDGAR |
| 2025-03-06 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | +14,000 | $0 | EDGAR |
| 2024-04-01 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −860 | -$4.0K | EDGAR |
| 2024-03-27 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −1,350 | -$6.3K | EDGAR |
| 2024-03-25 | Repare Therapeutics Inc. (RPTX) Delisted | Notice (144) | −2,210 | -$10.8K | EDGAR |
| 2024-03-04 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | +14,000 | $0 | EDGAR |
| 2023-06-09 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −3,535 | -$42.6K | EDGAR |
| 2023-06-07 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −1,200 | -$14.4K | EDGAR |
| 2023-06-06 | Repare Therapeutics Inc. (RPTX) Delisted | Notice (144) | −10,473 | -$123.1K | EDGAR |
| 2023-02-01 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | +24,550 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.